SUTTON, L.A., V. LJUNGSTROM, A. ENJUANES, D. CORTESE, A. SKAFTASON, E. TAUSCH, Kateřina STAŇO KOZUBÍK, F. NADEU, M. ARMAND, Jitka MALČÍKOVÁ, T. PANDZIC, J. FORSTER, Z. DAVIS, D. OSCIER, D. ROSSI, P. GHIA, J.C. STREFFORD, Šárka POSPÍŠILOVÁ, S. STILGENBAUER, F. DAVI, E. CAMPO, K. STAMATOPOULOS and R. ROSENQUIST. Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2021, vol. 106, No 3, p. 682-691. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2019.234716.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Authors SUTTON, L.A., V. LJUNGSTROM, A. ENJUANES, D. CORTESE, A. SKAFTASON, E. TAUSCH, Kateřina STAŇO KOZUBÍK (203 Czech Republic, belonging to the institution), F. NADEU, M. ARMAND, Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), T. PANDZIC, J. FORSTER, Z. DAVIS, D. OSCIER, D. ROSSI, P. GHIA, J.C. STREFFORD, Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), S. STILGENBAUER, F. DAVI, E. CAMPO, K. STAMATOPOULOS and R. ROSENQUIST.
Edition haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2021, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 11.047
RIV identification code RIV/00216224:14740/21:00119057
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3324/haematol.2019.234716
UT WoS 000624937600007
Keywords in English CLINICAL IMPACTRECURRENT MUTATIONSCLONAL EVOLUTIONLABORATORY STANDARDSTP53NOTCH1SF3B1CLLBIRC3PROGRESSION
Tags CF GEN, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 13/7/2021 10:18.
Abstract
Next-generation sequencing (NGS) has transitioned from research to clinical routine, yet the comparability of different technologies for mutation profiling remains an open question. We performed a European multicenter (n=6) evaluation of three amplicon-based NGS assays targeting 11 genes recurrently mutated in chronic lymphocytic leukemia. Each assay was assessed by two centers using 48 pre-characterized chronic lymphocytic leukemia samples; libraries were sequenced on the Illumina MiSeq instrument and bioinformatics analyses were centralized. Across all centers the median percentage of target reads >= 100x ranged from 94.299.8%. In order to rule out assay-specific technical variability, we first assessed variant calling at the individual assay level i.e., pairwise analysis of variants detected amongst partner centers. After filtering for variants present in the paired normal sample and removal of PCR/sequencing artefacts, the panels achieved 96.2% (Multiplicom), 97.7% (TruSeq) and 90% (HaloPlex) concordance at a variant allele frequency (VAF) 5%). We sought to investigate low-frequency mutations further by using a high-sensitivity assay containing unique molecular identifiers, which confirmed the presence of several minor subclonal mutations. Thus, while amplicon-based approaches can be adopted for somatic mutation detection with VAF 5%, after rigorous validation, the use of unique molecular identifiers may be necessary to reach a higher sensitivity and ensure consistent and accurate detection of low-frequency variants.
Links
GA19-15737S, research and development projectName: Alternativní mechanismy deregulace p53 dráhy u chronické lymfocytární leukémie
Investor: Czech Science Foundation, Alternative mechanisms of deregulation of the p53 pathway in chronic lymphocytic leukemia
LM2015091, research and development projectName: Národní centrum lékařské genomiky (Acronym: NCLG)
Investor: Ministry of Education, Youth and Sports of the CR
NV19-03-00091, research and development projectName: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
PrintDisplayed: 26/4/2024 20:48